- empe
- 2026-11-21
- No Comments
Resources
Finding TB is getting simpler. Knowing which drugs will work is not
Commentary on the WHO consolidated guidelines on tuberculosis, Module 3: diagnosis, second edition (2026)
On 3 November 2026, the WHO published the second edition of its consolidated guidelines on TB diagnosis. The newly released guidelines open with the problem at the heart of TB control: in 2024, an estimated 10.7 million people fell ill with TB, but only 8.3 million were diagnosed. Around 390,000 developed rifampicin-resistant or multidrug-resistant TB. The second edition does much to close the first gap. It does less, so far, for the second.
Detection is becoming simpler
The main change is a new class of molecular test for initial TB detection, recommended in place of smear microscopy. Tests in this class must use sealed reagents, need no more than three steps, run on battery power and require no laboratory infrastructure. On sputum, the first product in the class showed 85% sensitivity and 98% specificity. Tongue swabs are now recommended for people who cannot produce sputum. Where resources are constrained, programmes may also pool up to four sputum samples into a single test, though not for people living with HIV, children or those at risk of drug resistance.
Together, these changes should find more people with TB, earlier and in more places. But the new class is designed for sites without laboratories, and it does not detect drug resistance. The guideline says plainly that samples from all positive tests should be referred for drug susceptibility testing. Every person found closer to home is a sample that still has to travel, and it travels to the laboratories that will carry the volume.
Resistance testing is where the gap widens
Once rifampicin resistance is detected, the guideline states that further testing for fluoroquinolones and bedaquiline is “essential” to choose a shorter regimen. It calls fluoroquinolone testing essential before starting the all-oral shorter regimen.
For bedaquiline, the options are few:
- The only molecular approach recommended is targeted sequencing, done in centralised laboratories at US$ 120–257 per test.
- Its sensitivity for bedaquiline is 68%, based on just 31 resistant samples, and 9–21% of results are indeterminate.
- Susceptible results for bedaquiline, linezolid and clofazimine still need confirming by culture.
- For pretomanid, “culture-based DST is also required”.
Line probe assays: unchanged and still demanding
The LPA recommendations carry over from earlier editions:
- First-line LPAs are “not recommended” for direct testing of smear-negative sputum.
- Second-line LPAs may be used on smear-negative sputum from patients with confirmed MDR/RR-TB. Up to 44% of those results may be indeterminate, however, and need repeat or additional testing.
- Both remain reference-laboratory tests, requiring at least three separate rooms and highly skilled staff.
What the WHO asks for next
For the new class of tests, the WHO’s research priorities call for resistance tests that detect “at least rifampicin, and optimally isoniazid/MDR-TB, the fluoroquinolones and other TB drugs”. Tests that combine resistance detection for more than one drug are to be prioritised. The WHO also calls for its mutation catalogue to be updated, including for pretomanid.
What the WHO asks for next
At EMPE we benchmark our tests against LPAs, with culture as the gold standard. Our portfolio is built on our proprietary PLi-RCA technology (padlock probe-linked rolling circle amplification). It is designed for specificity: a padlock probe closes and amplifies only when it matches its target exactly.
- mfloDx™ MDR-TB, our CDSCO-approved test, detects TB and resistance to both rifampicin and isoniazid in a single test. It gives results in about three hours, read by eye.
- The CircuLOK range brings the same chemistry to open real-time PCR instruments that are easy to source. CircuLOK MDR-TB covers rifampicin and isoniazid, CircuLOK FLQ-TB covers fluoroquinolones, and CircuLOK pre-XDR-TB combines all three. Laboratories choose the resistance coverage that fits their patients and their budget, and expand it as their needs grow. The resistance tests will be available as an early access opportunity from the end of this year.
- CircuLOK TBDx is built for the other end of the network. The new class of tests is designed for peripheral sites with no laboratory, where each test is handled by hand, from sample collection and lysis to recording the result. That suits lower volumes. District and regional laboratories handling higher volumes need something different. CircuLOK TBDx is a highly accurate, lyophilised multiplex qPCR test with four gene targets. It runs on open qPCR instruments that are easy to source, in about 75 minutes, and scales from a single sample to 96 in one run. The cost per test falls as volume grows, and positive samples are reflexed to resistance testing. Used together with tests at the periphery, it lets programmes match each setting to the right tool. It will shortly be available as an early access opportunity, with full regulatory approval expected in 2027.
- Our pipeline extends PLi-RCA to the BPaLM drugs, with tests for bedaquiline, linezolid and pretomanid in development, which is where the guideline shows the widest gap. These tests will target only mutations with strong evidence of resistance. That makes them robust rule-in tests: a resistant result can be acted on with confidence. The panels can be extended as the WHO catalogue grows, in a simple qPCR format suited to testing at scale in decentralised settings.
Sequencing versus a qPCR format: head to head
Targeted next-generation sequencing is the only molecular option the WHO now recommends for bedaquiline, linezolid and clofazimine resistance. It is a genuine step forward, and it will remain essential for surveillance and for discovering new resistance mechanisms. But the guideline is candid about its limits: it is a high-complexity test, best suited to centralised laboratories with specialised skills and infrastructure. Users reported concern about affordability for low- and middle-income countries, and delays in low-caseload settings while samples wait to fill a batch. That is not a test that can reach every patient starting BPaLM.
Our BPaLM tests are designed to close that gap:
| Targeted NGS (as described by the WHO) | EMPE BPaLM tests (in development) | |
| Cost per test | US$ 120–257 | Target US$ 12–51: five to ten times less |
| Where it runs | Centralised reference laboratories | District and regional laboratories with open qPCR instruments |
| Complexity | High complexity; multi-step library preparation | Simple qPCR format |
| Time to result | 3–5 days, longer where samples wait to be batched | Run sizes flexible to demand; no waiting to fill a batch |
| What it reports | Every variant, including those of uncertain significance | Only mutations with strong evidence of resistance: robust rule-in |
| Pretomanid | Culture-based DST also required | Test in development |
Sequencing will keep its place in reference laboratories. But if bedaquiline, pretomanid and linezolid are to be protected at scale, resistance testing has to be affordable enough for every patient and simple enough for the laboratories that already diagnose TB. We believe EMPE will be first to deliver that.
This second edition makes TB easier to find. The next step is to make it just as simple to know which drugs will work, in the same laboratories where TB is diagnosed and without waiting weeks for culture.
Reference: World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis, second edition. Geneva: WHO; 2026. Published 3 November 2026. https://www.who.int/publications/i/item/9789240125421